Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Marseille – page 74

1 478 clinical trials in Marseille, France across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Marseille at a glance
1 478
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

1 478 trials in Marseille

Open in trial search

Multifocal motor neuropathy

Not recruiting

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Waldenstrom's macroglobulinaemia+1

Not recruiting

Evaluating Sonrotoclax Alone and Combined with Zanubrutinib for Patients with Previously Untreated or Relapsed/Refractory Waldenström Macroglobulinemia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib
  • Sponsor:BeOne Medicines AG

Diabetic retinal oedema

Not recruiting

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Eye103
  • Sponsor:Eyebiotech Limited

Squamous cell carcinoma of head and neck

Not recruiting

Study of Pucotenlimab with Becotatug Vedotin versus Becotatug Vedotin alone for patients with locally advanced head and neck squamous cell carcinoma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:PUCOTENLIMAB
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Essential tremor

Not recruiting

Study on the Effectiveness of BP1.4979 for Adults with Essential Tremor

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:N-[4-[2-[4-(3-Cyanophenyl)Piperazin-1-Yl]Ethyl]Cyclohexyl]-3-Methoxypropanamide
  • Sponsor:Bioprojet Pharma

Epileptic encephalopathy

Not recruiting

Title: Study of LP352 (bexicaserin) oral solution versus placebo for treating seizures in children and adults with Developmental and Epileptic Encephalopathies

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Longboard Pharmaceuticals Inc.

HIV infection

Not recruiting

Study on Lenacapavir for HIV Prevention in Individuals at Risk of HIV Infection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Emtricitabine
  • Sponsor:Gilead Sciences Inc.

Bladder transitional cell carcinoma

Not recruiting

Study on the Effectiveness of Durvalumab and BCG in Treating High-Risk, Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

HIV infection

Not recruiting

Study on the Safety and Effectiveness of Emtricitabine and Tenofovir Alafenamide for HIV-1 Prevention in Men and Transgender Women at Risk

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Emtricitabine
  • Sponsor:Gilead Sciences Inc.

Chronic graft versus host disease

Not recruiting

Study Comparing Axatilimab to Best Available Therapy for Patients with Chronic Graft-Versus-Host Disease After Two or More Treatments

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Adenocarcinoma gastric

Not recruiting

Study on the Effectiveness of Bemarituzumab and FLOT Chemotherapy for Patients with Resectable Gastric and Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Institut De Cancerologie De L Ouest

Pulmonary arterial hypertension

Not recruiting

Study on the Safety and Tolerability of Sotatercept for Patients with Pulmonary Arterial Hypertension

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Marseille

What the registry says about research in the country

01 Oncology Research

Studies focusing on innovative treatments for head and neck squamous cell carcinoma, examining novel therapies and combinations with radiotherapy. Research includes investigations into endometrial cancer and bladder cancer treatments.

  • Advanced tumor treatments
  • Immunotherapy combinations
  • Targeted therapies

Particular emphasis on combining immunotherapy with conventional treatments for improved patient outcomes.

02 Cardiovascular and Metabolic Disorders

Innovative research addressing heart failure prevention and treatment of acute myocardial infarction. Studies include new approaches for managing hypertriglyceridemia and chronic kidney disease.

  • Preventive cardiology
  • Emergency cardiac care
  • Metabolic conditions

Focus on developing novel therapeutic approaches and improving patient outcomes in cardiovascular health.

03 Neurological Conditions

Clinical investigations into multiple sclerosis treatment strategies and management of essential tremor. Research includes innovative approaches for Dravet Syndrome and neurological disorders.

  • Movement disorders
  • Autoimmune conditions
  • Seizure management

Emphasis on developing targeted therapies for various neurological conditions affecting both adults and children.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.